Mean SUVr for humeri and femurs at baseline and post-LPS challenge in non-SCD, SCD, and SCD mice co-treated with LPS and IgG isotype control or anti-P-selectin mAb. (A-D) Mean SUV for humeri divided by mean SUV for muscle for an SUV ratio normalized to background (humeri SUVr) at baseline and post-LPS for non-SCD (A), SCD (B), SCD + IgG isotype control (C), and SCD + anti-P-selectin mAb (D). *Denotes outlier identified by robust regression and outlier removal (ROUT, Q = 1%). (E-H) Mean SUV for femurs divided by mean SUV for muscle for an SUV ratio normalized to background (femurs SUVr) at baseline and post-LPS for non-SCD (E), SCD (F), SCD + IgG isotype control (G), and SCD + anti-P-selectin mAb (H) mice. *Denotes outlier identified by ROUT, Q = 1%. (A-H) Baseline and post-LPS means are shown as a red hollow circle with standard deviation (SD) error bars. Baseline and post-LPS groups were compared by using a paired 2-tailed Student t test. P < .05 was considered statistically significant. (I-J) SUVr fold-change from baseline to post-LPS (post-LPS/baseline) for humeri and femurs, respectively. The solid line depicts the mean of the non-SCD fold-change (no change, ∼1) and is shaded below the threshold. The data were compared using 1-way analysis of variance (ANOVA) with multiple comparisons by controlling false discovery rate (FDR) by a 2-stage linear step-up procedure from Benjamini, Krieger, and Yekutieli. FDR-corrected P < .05 was considered statistically significant. ANOVA for humeri and femurs were corrected for unequal variance. (I) Non-depicted P values for femurs fold-change: non-SCD vs SCD + IgG (P = .22), non-SCD vs SCD + anti-P-selectin mAb (P = .43), and SCD vs SCD + IgG (P = .53). (J) Non-depicted P values for femurs fold-change: non-SCD vs SCD + IgG (P = .07), non-SCD vs SCD + anti-P-selectin mAb (P = .52), and SCD vs SCD + IgG (P = .59).